SCHEMBL5117827

SCHEMBL5117827

CC(Nc1[c]cccn1)c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR55 Q9Y2T6 5/20 0.46
ATP1A1 P05023 1/20 0.46
ATP1B1 P05026 1/20 0.46
ATP1A3 P13637 1/20 0.46
ATP1B2 P14415 1/20 0.46
ATP1A2 P50993 1/20 0.46
ATP1B3 P54709 1/20 0.46
FXYD2 P54710 1/20 0.46
ATP1A4 Q13733 1/20 0.46
MAPKAPK2 P49137 1/20 0.42
EGFR P00533 3/20 0.41
HTR7 P34969 2/20 0.41
HTR2C P28335 1/20 0.41
MEN1 O00255 1/20 0.41
CLK1 P49759 1/20 0.41
KMT2A Q03164 1/20 0.41
CCNE2 O96020 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
GPR39 O43194 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3336236 0.78 GPR55 (0.51) GPR55ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL6015000 0.76 IDO1 (0.34)
SCHEMBL14840619 0.74 GPR55 (0.58) GPR55ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL26614624 0.74 ALDH1A1 (0.53) GPR55ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL8725425 0.73 MAPT (0.45) MEN1KMT2A
SCHEMBL14954416 0.72 JAK2 (0.56) GPR55MAPKAPK2MEN1CLK1KMT2A
SCHEMBL14954415 0.72 JAK2 (0.56) GPR55MAPKAPK2MEN1CLK1KMT2A
SCHEMBL28794316 0.71 GPR55 (0.48) GPR55ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL5787428 0.71 GPR55 (0.48) GPR55ATP1A1ATP1B1ATP1A3ATP1B2
SCHEMBL5469093 0.69 GPR55 (0.50) GPR55HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324252-B2 Pyrazolylaminopyridine derivatives useful as kinase inhibitors ASTRAZENECA AB (SE) 2012-12-04 US disclosed
US-20080139561-A1 e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases ASTRAZENECA AB (SE) 2008-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139561-A1 e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases CNKSR1, LTK, MUSK GPR55 1056/4885ATP1A1 2333/4885ATP1B1 2601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.